Ashraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.
Ashraf Badros, MBCHB
Advertisement
Articles by Ashraf Badros, MBCHB
Ashraf Badros, MBCHB, discusses the addition of subcutaneous daratumumab to lenalidomide vs lenalidomide alone in newly diagnosed myeloma following ASCT.
Advertisement
Latest Updated Articles
Dr Badros on the Design of the AURIGA Study of Daratumumab/Lenalidomide in Newly Diagnosed MyelomaPublished: October 30th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5